Product nameAnti-CD45R antibody [RA3-6B2] (violetFluor™ 450)
See all CD45R primary antibodies
DescriptionRat monoclonal [RA3-6B2] to CD45R (violetFluor™ 450)
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Mouse
The details of the immunogen for this antibody are not available.
- Flow cyt: Mouse C57Bl/6 splenocytes.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.16% Sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin
Concentration information loading...
Purification notesPurified from tissue culture supernatant. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.
Light chain typekappa
- Anti-CD45R antibody [RA3-6B2] (PerCP/Cy5.5®) (ab210342)
- Anti-CD45R antibody [RA3-6B2] (FITC) (ab234244)
- Anti-CD45 antibody [RA3-6B2] (redFluor™ 710) (ab242264)
- Anti-CD45R antibody [RA3-6B2] (FITC) (ab24897)
- Anti-CD45R antibody [RA3-6B2] (ab64100)
- Anti-CD45R antibody [RA3-6B2] (Allophycocyanin/Cy7 ®) (ab79107)
Our Abpromise guarantee covers the use of ab253061 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.
Use at 0.5 μg per reaction.
FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.
DomainThe first PTPase domain interacts with SKAP1.
modificationsHeavily N- and O-glycosylated.
Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
- Information by UniProt
- B220 antibody
- CD45 antibody
- CD45 antigen antibody
ab253061 has not yet been referenced specifically in any publications.